CADRx Precision Medicines

CADRx Precision Medicines is a private biopharmaceutical company focused on precision prevention and localized treatment of premalignant and malignant oral lesions. The company is developing biocompatible, biodegradable, unidirectional topical drug delivery systems manufactured with 3D pharmaceutical printing to deliver very low doses of approved drugs directly to mucosal or dermal tissue while minimizing systemic exposure. Its lead effort appears centered on LeukoPlax, a mucoadhesive patch approach for oral leukoplakia and related oral potentially malignant disorders, with supporting preclinical work involving mycophenolic acid and oxaliplatin. CADRx also positions its platform as a partnering solution for safer dosage forms and precision dosing of existing medicines. Overall, the company sits at the intersection of drug repurposing, localized drug delivery, and additive pharmaceutical manufacturing.